This systematic review aims to critically evaluate and synthesize the available evidence on the impact of PDE-5 inhibitors on cardiovascular outcomes, including mortality, myocardial infarction, stroke, and blood pressure, in patients with both ED and coexisting CVD. Here, PDE5A is linked to myocardial infarction.